The effectiveness of split tablet dosing versus alternate-day dosing of warfarin: A randomized control trial
Phase 4
Completed
- Conditions
- Blood INRTTRWarfarin adjustment
- Registration Number
- TCTR20161212001
- Lead Sponsor
- Siriraj Research Development Fund (Managed by Routine to Research: R2R)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 66
Inclusion Criteria
The anticoagulated patients who followed up at the outpatient clinic of the Division of Cardio-Thoracic Surgery, Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand
Eligible patients had six months or longer history of stable therapeutic INR levels of 2.0 to 3.0 achieved by the specific weekly dose of warfarin in the dosage protocol (14, 17.5, 21, 24.5, 28, 31.5 mg/week) and could comply with 6 months follow up protocol.
Exclusion Criteria
The patients whose a period of warfarin discontinuation was possibly needed were excluded.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Time in therapeutic range: TTR At 6-week interval for 6 months Rosendaal methods
- Secondary Outcome Measures
Name Time Method The dosage change incidence, INR levels, the bleeding and thromboembolic events of the warfarin, the compliance and adherence of the participants. At 6-week interval for 6 months Incident